Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01987570|
Recruitment Status : Completed
First Posted : November 19, 2013
Last Update Posted : September 8, 2016
Generating critical levels of power is a prerequisite for performing simple daily activities, such as rising from a chair or climbing stairs. For a young healthy person these activities can be performed easily, however after a prolonged period of forced inactivity (such as during the recovery from a sports injury, prolonged bed rest or spaceflight) a loss of muscle mass occurs. It has been suggested that this loss may be triggered by oxidative stress. An enzyme involved in the production of free radicals in various experimental models, including immobilization, is xanthine oxidase (XO). Although allopurinol is an inhibitor of XO widely used in clinical practice, its effect on the maintenance of muscle mass after an immobilization protocol is unknown. Thus, the major aim of this clinical trial is to determine the effect of allopurinol administration on the prevention of muscle mass loss in immobilized subjects.
This is a prospective, randomized study in which fifty young male subjects (aged between 25 and 40 years) diagnosed with grade II ankle sprain will be recruited. After immobilization the patients will be assigned randomly to one of two experimental groups, one treated with allopurinol (n=25) and the other with placebo (n=25). The dosage of allopurinol will be the same as recommended for gout patients, i.e. 300 mg/day orally, during all the immobilization period, which will last fifteen days. This medication will be delivered to the patients when they agree to participate in the clinical trial. They will be immobilized by posterior knee splint, preventing use of that leg.
We will determine muscle mass loss by performing two magnetic resonances of both legs before and after the immobilization period. We will also take two blood samples (before and after immobilization) to measure oxidative stress parameters (malondialdehyde, protein carbonyls, and XO activity), inflammatory parameters (IL-6, C-reactive protein and 1-antichymotrypsin), as well as vitamin D levels.
|Condition or disease||Intervention/treatment||Phase|
|Patients With Grade II Ankle Sprain||Drug: Allopurinol Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||53 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.|
|Study Start Date :||April 2012|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||July 2016|
One tablet of allopurinol is administrated orally at a dose of 300 mg/24 hours, during the time that the patient remains immobilized for 15 days.
Placebo Comparator: Placebo
One tablet/24 hours of placebo orally, during the time that the patient remains immobilized for 15 days.
- Muscle mass loss [ Time Frame: Day 0 and day 15 ]Checks the loss of muscle mass percentage with Magnetic Resonance before and after treatment.
- The role of xanthine oxidase in the loss of muscle mass [ Time Frame: Day 0 and day 15 ]Measure xanthine oxidase activity in plasma
- size of the leg muscles in a group of immobilized subjects. [ Time Frame: Day 0 and day 15 ]Checks the loss of muscle mass size with Magnetic Resonance before and after treatment.
- oxidative stress parameters [ Time Frame: Day 0 and day 15 ]Glutathione (GSH), glutathione disulfide (GSSG), malondialdehyde (MDA) and oxidized proteins, after a period of immobilization of 15 days duration.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01987570
|University of Valencia|
|Valencia, Spain, 46010|
|Hospital Universitari i Politècnic La Fe|
|Valencia, Spain, 46026|
|Study Director:||JOSÉ VIÑA, MD PhD (HON)||University of Valencia|